Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer

October 16, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the existing marketing authorization for abiraterone acetate to include use in combination with prednisone/prednisolone and androgen deprivation therapy (ADT) in men with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer. The European Commission (EC) has already approved abiraterone … (leggi tutto)